Please login to the form below

Not currently logged in
Email:
Password:

cardiovascular disease

This page shows the latest cardiovascular disease news and features for those working in and with pharma, biotech and healthcare.

Lilly trumpets Trulicity heart data in face-off with Novo Nordisk

Lilly trumpets Trulicity heart data in face-off with Novo Nordisk

cardiovascular disease, says Lilly, as less than a third (31%) of patients had established heart disease at enrolment. ... 2 diabetes with established cardiovascular disease based on data from the EMPA-REG trial, and all the big diabetes players have

Latest news

More from news
Approximately 16 fully matching, plus 252 partially matching documents found.

Latest Intelligence

  • The threat of antimicrobial resistance The threat of antimicrobial resistance

    the low commercial value placed on antibiotic drugs compared to more lucrative sectors such as cardiovascular disease and cancer. ... By January 2018, the US Centers for Disease Control and Prevention had reported 29 cases of MCR resistance identified

  • Pharma deals continue to slide Pharma deals continue to slide

    Cerecor has sold its kappa opioid receptor antagonist in phase 2 to Janssen (J&J) and Xoma has licensed its interleukin 1 beta intellectual property for cardiovascular disease to Novartis plus ... Gevokizumab plus IP for use of IL-1 beta targeting

  • Perfecting the pharmaceutical pipeline with AI Perfecting the pharmaceutical pipeline with AI

    This has a knock-on effect for research around rare disease types specifically. ... For example, a drug being used for cardiovascular disease might be found to have useful qualities for neurological diseases.

  • The EarthWorks: New ways to improve patient care The EarthWorks: New ways to improve patient care

    Keeping people well and preventing illness. Technology is only interesting socially when it is boring technologically; we have to have scale to begin to prevent disease on a population level. ... cardiovascular disease and transplantation.

  • Deal Watch March 2016 Deal Watch March 2016

    Padlock's technology targets autoimmune disorders with protein/peptidyl arginine deiminase (PAD) inhibitors and offers the potential to prevent disease development in patients with early stage disease. ... Co-development. $130. Lipigon/ AstraZeneca.

More from intelligence
Approximately 0 fully matching, plus 18 partially matching documents found.

Latest appointments

  • Sanifit appoints Alexander Gold chief medical officer Sanifit appoints Alexander Gold chief medical officer

    Alex arrives here with first class operational and clinical development expertise in novel drug therapies, targeting cardiovascular and metabolic disease and kidney disease amongst others.

  • Leading Edge bolsters its delivery team Leading Edge bolsters its delivery team

    Francesca Worthington joins the group as an account manager after working across a variety of medical communication programmes and in a number of therapy areas, including haematology, ophthalmology, cardiovascular disease and

  • MyoKardia appoints COO and medical affairs VP MyoKardia appoints COO and medical affairs VP

    Prior to this, Dr Lee was therapeutic area head for cardiovascular, metabolic, respiratory and infectious disease programmes at Genentech. ... Their expertise and counsel will broaden our base of leadership and support our mission to change the world for

  • The Medicines Company appoints Biogen's Tony Kingsley The Medicines Company appoints Biogen's Tony Kingsley

    He will also serve at the company, which focuses on serious infectious disease care, acute cardiovascular care, and surgery and perioperative care, as its president, taking over from Glenn Sblendorio, who

  • MedImmune appoints Dr Christopher Rhodes MedImmune appoints Dr Christopher Rhodes

    AstraZeneca's biologics research and development arm MedImmune has appointed Dr Christopher Rhodes as vice president, cardiovascular and metabolic disease (CVMD) research. ... exciting time for our Cardiovascular and Metabolic Disease therapeutic area.

More from appointments
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 13 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics